Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-207-9 | CAS number: 52829-07-9
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The test substance is expected to be absorbed to some extent in the rat and dog, distributed, metabolized and excreted with no indication of accumulation.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
The following prediction for the metabolic fate of the test substance can be made: The test substance has amphiphilic properties and is expected to be well absorbed from the gastrointestinal tract and consequently bioavailable to some extent. Metabolic degradation of Phase I hydrolysis is assumed, generating 2,2,6,6-Tetramethylpiperidin-4-ol (HTMP) and sebacic acid (decanedioic acid) as the main metabolites, leading to phase II reactions and rapid urinary and/or biliary elimination.
The metabolite HTMP showed much less affinity to Ca-channel and acetylcholine receptors than the parent compound. This is reflected the absence of cardio-/neurotoxicity after oral administration in contrast to parenteral treatment or in-vitro study designs [1, 2].
This prediction is in line with the results of the acute toxicity studies in rats and repeat-dose toxicology studies in both rats and dogs showing low acute toxicity and absence of relevant findings after repeated administration in clinical pathology and post mortem examinations. In dogs only, hepatocellular hypertrophy of a minimal degree was observed. In rats deaths occurred at excessive dosages of ≥ 600 mg/kg, accompanied by clinical signs of poor general condition, that in single cases could also be interpreted as signs of neurotoxicity. All other findings seen can be attributed to palatability problems in the in-feed studies in rats and dogs.
1. Glossmann H et al. (1993) Proc. Nat. Acad. Sci. USA, Vol 90, 9523 -9527
2. Sotonyi P et al. (2004) Tox. Sciences 77, 368 -374
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
